Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics has received marketing authorization from the Paul Ehrlich Institut in Germany for its innovative subcutaneous grass pollen allergen immunotherapy, Grassmuno. This approval marks the first of its kind under Germany’s TAV program and is expected to significantly impact the German seasonal allergy market, projected to reach approximately US$1 billion by 2030. The company plans to commercialize Grassmuno in Germany by Q1 2026 and is exploring further regulatory submissions in other global markets. This development is seen as a pivotal moment for Allergy Therapeutics, reinforcing its commitment to clinical excellence and expanding its market presence.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, specializing in the treatment and diagnosis of allergic disorders. The company focuses on aluminium-free immunotherapies with the potential to cure diseases and markets its proprietary and third-party products across nine major European countries and through distribution agreements in ten additional countries.
Average Trading Volume: 381,569
Technical Sentiment Signal: Buy
Current Market Cap: £629.5M
See more insights into AGY stock on TipRanks’ Stock Analysis page.